Skip to content

Study · Observational study · 2024

17 results

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.

He L, Li Q, Yang Y, Li J, Luo W, Huang Y, Zhong X

Frontiers in pharmacology8 Jul 2024Cited by 34 (Europe PMC)

PMID39040467 (opens in a new tab)PMCIDPMC11260617 (opens in a new tab)DOI10.3389/fphar.2024.1416985 (opens in a new tab)PepBankPUB-39040467
Download PDFPubMedAsk about this study
Jump to 17 results

Summary

Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are employed extensively in the management of type 2 diabetes and obesity. However, there is a paucity of real-world data on their safety and tolerability for metabolic and nutritional adverse events in large sample populations. This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Methods: AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023. The reported odds ratio (ROR), proportional reporting ratio (PRR), Empirical Bayesian Geometric Mean and Bayesian Confidence Propagation Neural Network were employed to identify AE signals. Results: A system organ class of metabolism and nutrition disorders was employed to filter AE reports, resulting in the identification of 10,450 reports for exenatide, 2,860 reports for liraglutide, 240 reports for albiglutide, 4,847 reports for dulaglutide, 2,905 reports for semaglutide, 1,089 reports for tirzepatide, and 13 reports for lixisenatide. Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide (ROR, 2.78; 95%CI, 2.69), and exenatide (ROR, 2.15; 95%CI, 2.11) were associated with metabolism and nutrition disorders. The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22). Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%). The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs (p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile. Conclusion: Our study suggests that exenatide, liraglutide, and semaglutide are more susceptible to metabolic and nutritional AEs than other GLP-1 RAs. Liraglutide, dulaglutide, semaglutide, and tirzepaptide's potential to induce dehydration, necessitates special attention. Despite certain deficiencies, GLP-1 RAs have considerable potential for the treatment of eating disorders.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

  1. 01HumanObservational studySafety outcome

    In FAERS, dulaglutide had 4,847 metabolism and nutrition disorder reports.

    In plain wordsIn adverse-event records, dulaglutide had 4,847 reports concerning metabolism and nutrition disorders.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableMetabolism and nutrition disorder reports
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reports
    4847 reports
    FAERS metabolism and nutrition disorders, dulaglutide

    Source sentences

    Summary
    4,847 reports for dulaglutide
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  2. 02HumanObservational studySafety outcome

    In FAERS, liraglutide had 2,860 metabolism and nutrition disorder reports.

    In plain wordsIn adverse-event records, liraglutide had 2,860 reports concerning metabolism and nutrition disorders.

    Peptide
    Liraglutide
    Outcome
    Not applicableMetabolism and nutrition disorder reports
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reports
    2860 reports
    FAERS metabolism and nutrition disorders, liraglutide

    Source sentences

    Summary
    2,860 reports for liraglutide
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  3. 03HumanObservational studySafety outcome

    In FAERS, semaglutide had 2,905 metabolism and nutrition disorder reports.

    In plain wordsIn adverse-event records, semaglutide had 2,905 reports concerning metabolism and nutrition disorders.

    Peptide
    Semaglutide
    Outcome
    Not applicableMetabolism and nutrition disorder reports
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reports
    2905 reports
    FAERS metabolism and nutrition disorders, semaglutide

    Source sentences

    Summary
    2,905 reports for semaglutide
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  4. 04HumanObservational studySafety outcome

    In FAERS, tirzepatide had 1,089 metabolism and nutrition disorder reports.

    In plain wordsIn adverse-event records, tirzepatide had 1,089 reports concerning metabolism and nutrition disorders.

    Peptide
    Tirzepatide
    Outcome
    Not applicableMetabolism and nutrition disorder reports
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reports
    1089 reports
    FAERS metabolism and nutrition disorders, tirzepatide

    Source sentences

    Summary
    1,089 reports for tirzepatide
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  5. 05HumanObservational studySafety outcome

    In FAERS, semaglutide was linked to metabolism and nutrition disorders, with a reporting odds ratio of 3.34.

    In plain wordsIn adverse-event records, semaglutide was linked to increased reporting odds for metabolism and nutrition disorders.

    Peptide
    Semaglutide
    Outcome
    IncreaseMetabolism and nutrition disorder reporting odds
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    ROR
    3.34 ratio
    semaglutide

    Source sentences

    Summary
    Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide (ROR, 2.78; 95%CI, 2.69), and exenatide (ROR, 2.15; 95%CI, 2.11) were associated with metabolism and nutrition disorders.
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  6. 06HumanObservational studySafety outcome

    In FAERS, liraglutide was linked to metabolism and nutrition disorders, with a reporting odds ratio of 2.78.

    In plain wordsIn adverse-event records, liraglutide was linked to increased reporting odds for metabolism and nutrition disorders.

    Peptide
    Liraglutide
    Outcome
    IncreaseMetabolism and nutrition disorder reporting odds
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    ROR
    2.78 ratio
    liraglutide

    Source sentences

    Summary
    Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide (ROR, 2.78; 95%CI, 2.69), and exenatide (ROR, 2.15; 95%CI, 2.11) were associated with metabolism and nutrition disorders.
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  7. 07HumanObservational studySafety outcome

    In FAERS, investigators detected 22 metabolic and nutritional adverse event signals for dulaglutide.

    In plain wordsIn adverse-event records, investigators detected 22 metabolic and nutritional safety signals for dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdverse event signal count
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Signals
    22 signals
    dulaglutide

    Source sentences

    Summary
    The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  8. 08HumanObservational studySafety outcome

    In FAERS, investigators detected 16 metabolic and nutritional adverse event signals for liraglutide.

    In plain wordsIn adverse-event records, investigators detected 16 metabolic and nutritional safety signals for liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableAdverse event signal count
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Signals
    16 signals
    liraglutide

    Source sentences

    Summary
    The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  9. 09HumanObservational studySafety outcome

    In FAERS, investigators detected 20 metabolic and nutritional adverse event signals for semaglutide.

    In plain wordsIn adverse-event records, investigators detected 20 metabolic and nutritional safety signals for semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse event signal count
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Signals
    20 signals
    semaglutide

    Source sentences

    Summary
    The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  10. 10HumanObservational studySafety outcome

    In FAERS, investigators detected 11 metabolic and nutritional adverse event signals for tirzepatide.

    In plain wordsIn adverse-event records, investigators detected 11 metabolic and nutritional safety signals for tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAdverse event signal count
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Signals
    11 signals
    tirzepatide

    Source sentences

    Summary
    The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  11. 11HumanObservational studySafety outcome

    In FAERS dulaglutide reports, dehydration was the most frequent adverse event contributing to serious outcomes (434; 20.90%).

    In plain wordsIn dulaglutide adverse-event records, dehydration was the most frequent event contributing to serious outcomes.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDehydration contributing to serious outcomes
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Dehydration
    434 reports
    dulaglutide serious outcomes
    Dehydration
    20.9%
    dulaglutide serious outcomes

    Source sentences

    Summary
    Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  12. 12HumanObservational studySafety outcome

    In FAERS liraglutide reports, dehydration was the most frequent adverse event contributing to serious outcomes (318; 23.93%).

    In plain wordsIn liraglutide adverse-event records, dehydration was the most frequent event contributing to serious outcomes.

    Peptide
    Liraglutide
    Outcome
    Not applicableDehydration contributing to serious outcomes
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Dehydration
    318 reports
    liraglutide serious outcomes
    Dehydration
    23.93%
    liraglutide serious outcomes

    Source sentences

    Summary
    Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  13. 13HumanObservational studySafety outcome

    In FAERS semaglutide reports, dehydration was the most frequent adverse event contributing to serious outcomes (370; 25.10%).

    In plain wordsIn semaglutide adverse-event records, dehydration was the most frequent event contributing to serious outcomes.

    Peptide
    Semaglutide
    Outcome
    Not applicableDehydration contributing to serious outcomes
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Dehydration
    370 reports
    semaglutide serious outcomes
    Dehydration
    25.1%
    semaglutide serious outcomes

    Source sentences

    Summary
    Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  14. 14HumanObservational studySafety outcome

    In FAERS tirzepatide reports, dehydration was the most frequent adverse event contributing to serious outcomes (70; 32.86%).

    In plain wordsIn tirzepatide adverse-event records, dehydration was the most frequent event contributing to serious outcomes.

    Peptide
    Tirzepatide
    Outcome
    Not applicableDehydration contributing to serious outcomes
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Dehydration
    70 reports
    tirzepatide serious outcomes
    Dehydration
    32.86%
    tirzepatide serious outcomes

    Source sentences

    Summary
    Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%).
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  15. 15HumanObservational studySafety outcome

    In FAERS, dulaglutide dehydration reports showed an early failure-type Weibull profile.

    In plain wordsIn dulaglutide adverse-event records, the dehydration timing analysis showed an early failure-type pattern.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDehydration onset profile
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs (p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile.
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  16. 16HumanObservational studySafety outcome

    In FAERS, liraglutide dehydration reports showed an early failure-type Weibull profile.

    In plain wordsIn liraglutide adverse-event records, the dehydration timing analysis showed an early failure-type pattern.

    Peptide
    Liraglutide
    Outcome
    Not applicableDehydration onset profile
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs (p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile.
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.
  17. 17HumanObservational studySafety outcome

    In FAERS, semaglutide dehydration reports showed an early failure-type Weibull profile.

    In plain wordsIn semaglutide adverse-event records, the dehydration timing analysis showed an early failure-type pattern.

    Peptide
    Semaglutide
    Outcome
    Not applicableDehydration onset profile
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs (p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile.
    2 context sentences
    Summary · context
    This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
    Summary · context
    AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 6Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 5

    22 Oct 2026, 02:25 UTC

    Study results updated

  3. Versions 2 to 4

    21 Oct 2026, 18:59 UTC

    The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.